debt_leverage_profile
Near-zero debt; cash-funded clinical-stage biotech with no material long-term debt obligations as of 2024.
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; no significant floating-rate debt. Higher rates modestly reduce cash runway yield but have negligible P&L impact.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Single-source API manufacturer (likely European/Indian CMO); 2) Radioactive isotope supply chain dependent on limited global nuclear reactor sites.
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue; no international revenue markets yet. Currency devaluation exposure is effectively zero at current stage.
Inferred
Agent_Inference
geographic_footprint
US-domiciled, US-centric clinical trials; no meaningful international revenue footprint. Minimal sovereign currency devaluation risk.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High; single CDMO/API supplier for camsirubicin likely exceeds 30% of operational input cost with limited near-term substitutability.
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage pharma; no cloud-native product. Cloud disruption would impair operations but not destroy core drug development assets.
Inferred
Agent_Inference
business_model_type_secondary
R&D/licensing-oriented biotech; secondary model is potential out-licensing or partnership deals upon clinical data readout.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; minimal SaaS dependencies. Primary lock-in is regulatory/CMC documentation tied to specific manufacturer.
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; revenue model is drug development/licensing, not a token or investment contract scheme. Howey Test risk is negligible.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited exposure; clinical trial data subject to FDA/ICH GCP standards. GDPR exposure exists for EU trial sites but is manageable.
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal; small-cap niche oncology/radiopharma developer with no dominant market position. No material antitrust exposure.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently pre-revenue. Future revenue expected from milestone payments and royalties (transactional/event-driven), not recurring subscriptions.
Inferred
Agent_Inference
monetization_vector
Drug licensing milestones and royalties upon commercialization; potential partnership upfront payments as near-term monetization.
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future drug pricing will depend on oncology reimbursement benchmarks, ICER analysis, and payer negotiations.
Inferred
Agent_Inference
pricing_power_rating
Moderate-to-high potential if approved; orphan/specialty oncology drugs command premium pricing with limited generic competition near-term.
Inferred
Agent_Inference
target_gross_margin_bracket
Pharma royalty/licensing model targets 70–90% gross margins post-commercialization; manufacturing COGS will determine final bracket.
Inferred
Agent_Inference
churn_vulnerability_index
Not applicable; no subscription product or free-tier offering. No free-rider leakage problem in clinical-stage biotech model.
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear; virtual/lean organization (~15 FTEs). Revenue growth via licensing/royalties does not require proportional headcount scaling.
Inferred
Agent_Inference
marginal_cost_of_growth
Very low marginal cost per revenue dollar in royalty scenario; clinical advancement costs are lumpy but headcount addition is minimal.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Monopar is not a franchise business model.
Inferred
Agent_Inference
customer_acquisition_metric
Not applicable pre-revenue; at 10x scale, partner/licensee acquisition cost would be low relative to deal value in pharma BD context.
Inferred
Agent_Inference
network_effect_present
No network effects present; drug efficacy and IP exclusivity, not user networks, drive competitive moat.
Inferred
Agent_Inference
asset_efficiency_ratio
-9.7% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate; oncology drugs are recession-resistant at commercial stage, but clinical funding and partnership appetite can tighten in downturns.
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical/biotech licensing partners and acquirers as primary 'customers' in business development context.
Inferred
Agent_Inference
customer_segment_secondary
Oncology patients and treating oncologists as end-user segment upon commercialization; currently no direct customer revenue.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated almost entirely to R&D (clinical trials, CMC); no legacy infrastructure. Capex is forward-looking, not legacy-maintenance spending.
Inferred
Agent_Inference
sec_cik
0001645469
High
SEC-EDGAR
ticker
MNPR
High
SEC-EDGAR